Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

Musoro, JZ, Sodergren, SC, Coens, C, Pochesci, A, Terada, M, King, MT, Sprangers, MAG, Groenvold, M, Cocks, K, Velikova, G, Flechtner, H-H & Bottomley, A 2020, 'Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy', Colorectal Disease, bind 22, nr. 12, s. 2278-2287. https://doi.org/10.1111/codi.15295

APA

Musoro, J. Z., Sodergren, S. C., Coens, C., Pochesci, A., Terada, M., King, M. T., Sprangers, M. A. G., Groenvold, M., Cocks, K., Velikova, G., Flechtner, H-H., & Bottomley, A. (2020). Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy. Colorectal Disease, 22(12), 2278-2287. https://doi.org/10.1111/codi.15295

CBE

Musoro JZ, Sodergren SC, Coens C, Pochesci A, Terada M, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner H-H, Bottomley A. 2020. Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy. Colorectal Disease. 22(12):2278-2287. https://doi.org/10.1111/codi.15295

MLA

Vancouver

Author

Musoro, J Z ; Sodergren, S C ; Coens, C ; Pochesci, A ; Terada, M ; King, M T ; Sprangers, M A G ; Groenvold, M ; Cocks, K ; Velikova, G ; Flechtner, H-H ; Bottomley, A. / Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy. I: Colorectal Disease. 2020 ; Bind 22, Nr. 12. s. 2278-2287.

Bibtex

@article{5356338d4e0f49d6903c003efebc7aa5,
title = "Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy",
abstract = "AIM: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses the health-related quality of life of patients in cancer trials. There are currently no minimally important difference (MID) guidelines for the EORTC QLQ-C30 for colorectal cancer (CRC). This study aims to estimate MIDs for the EORTC QLQ-C30 scales in patients with advanced CRC treated with chemotherapy and enrolled in clinical trials.METHOD: The data were obtained from three published EORTC trials that treated CRC patients using chemotherapy. Potential anchors were selected from clinical variables based on their correlation with EORTC QLQ-C30 scales. Anchor-based MIDs for within-group change and between-group change were estimated via the mean change method and linear regression, respectively, and summarized using weighted correlation. Distribution-based MIDs were also examined.RESULTS: Anchor-based MIDs were determined for deterioration in 8 of the 14 EORTC QLQ-C30 scales and in 9 scales for improvement, and varied by scale, direction of change and anchor. MIDs for improvement (deterioration) ranged from 6 to 18 (-11 to -5) points for within-group change and 5 to 15 (-10 to -4) for between-group change. Summarized MIDs (in absolute values) per scale mostly ranged from 5 to 10 points.CONCLUSIONS: These findings have clinical relevance for the interpretation of treatment efficacy and the design of clinical trials by informing sample size requirements.",
keywords = "Advanced colorectal cancer, EORTC QLQ-C30, clinical anchors, health-related quality of life (HRQOL), minimally important difference (MID)",
author = "Musoro, {J Z} and Sodergren, {S C} and C Coens and A Pochesci and M Terada and King, {M T} and Sprangers, {M A G} and M Groenvold and K Cocks and G Velikova and H-H Flechtner and A Bottomley",
note = "Publisher Copyright: {\textcopyright} 2020 The Association of Coloproctology of Great Britain and Ireland Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = dec,
doi = "10.1111/codi.15295",
language = "English",
volume = "22",
pages = "2278--2287",
journal = "Colorectal Disease",
issn = "1462-8910",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "12",

}

RIS

TY - JOUR

T1 - Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy

AU - Musoro, J Z

AU - Sodergren, S C

AU - Coens, C

AU - Pochesci, A

AU - Terada, M

AU - King, M T

AU - Sprangers, M A G

AU - Groenvold, M

AU - Cocks, K

AU - Velikova, G

AU - Flechtner, H-H

AU - Bottomley, A

N1 - Publisher Copyright: © 2020 The Association of Coloproctology of Great Britain and Ireland Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/12

Y1 - 2020/12

N2 - AIM: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses the health-related quality of life of patients in cancer trials. There are currently no minimally important difference (MID) guidelines for the EORTC QLQ-C30 for colorectal cancer (CRC). This study aims to estimate MIDs for the EORTC QLQ-C30 scales in patients with advanced CRC treated with chemotherapy and enrolled in clinical trials.METHOD: The data were obtained from three published EORTC trials that treated CRC patients using chemotherapy. Potential anchors were selected from clinical variables based on their correlation with EORTC QLQ-C30 scales. Anchor-based MIDs for within-group change and between-group change were estimated via the mean change method and linear regression, respectively, and summarized using weighted correlation. Distribution-based MIDs were also examined.RESULTS: Anchor-based MIDs were determined for deterioration in 8 of the 14 EORTC QLQ-C30 scales and in 9 scales for improvement, and varied by scale, direction of change and anchor. MIDs for improvement (deterioration) ranged from 6 to 18 (-11 to -5) points for within-group change and 5 to 15 (-10 to -4) for between-group change. Summarized MIDs (in absolute values) per scale mostly ranged from 5 to 10 points.CONCLUSIONS: These findings have clinical relevance for the interpretation of treatment efficacy and the design of clinical trials by informing sample size requirements.

AB - AIM: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses the health-related quality of life of patients in cancer trials. There are currently no minimally important difference (MID) guidelines for the EORTC QLQ-C30 for colorectal cancer (CRC). This study aims to estimate MIDs for the EORTC QLQ-C30 scales in patients with advanced CRC treated with chemotherapy and enrolled in clinical trials.METHOD: The data were obtained from three published EORTC trials that treated CRC patients using chemotherapy. Potential anchors were selected from clinical variables based on their correlation with EORTC QLQ-C30 scales. Anchor-based MIDs for within-group change and between-group change were estimated via the mean change method and linear regression, respectively, and summarized using weighted correlation. Distribution-based MIDs were also examined.RESULTS: Anchor-based MIDs were determined for deterioration in 8 of the 14 EORTC QLQ-C30 scales and in 9 scales for improvement, and varied by scale, direction of change and anchor. MIDs for improvement (deterioration) ranged from 6 to 18 (-11 to -5) points for within-group change and 5 to 15 (-10 to -4) for between-group change. Summarized MIDs (in absolute values) per scale mostly ranged from 5 to 10 points.CONCLUSIONS: These findings have clinical relevance for the interpretation of treatment efficacy and the design of clinical trials by informing sample size requirements.

KW - Advanced colorectal cancer

KW - EORTC QLQ-C30

KW - clinical anchors

KW - health-related quality of life (HRQOL)

KW - minimally important difference (MID)

UR - http://www.scopus.com/inward/record.url?scp=85089917201&partnerID=8YFLogxK

U2 - 10.1111/codi.15295

DO - 10.1111/codi.15295

M3 - Journal article

C2 - 32767619

VL - 22

SP - 2278

EP - 2287

JO - Colorectal Disease

JF - Colorectal Disease

SN - 1462-8910

IS - 12

ER -

ID: 61353295